Pharmaceutical Statistics

Cover image for Vol. 13 Issue 4

Editors-in-Chief: Oliver Keene, Lisa LaVange and Gerd Rosenkranz

Impact Factor: 1.102

ISI Journal Citation Reports © Ranking: 2013: 45/119 (Statistics & Probability); 201/254 (Pharmacology & Pharmacy)

Online ISSN: 1539-1612

Recently Published Issues

See all

Pharmaceutical Statistics OnlineOpen

OnlineOpen – The Open Access Option for Authors

OnlineOpen is available to authors who wish to make their article open access, free to read, download and share via Wiley Online Library and PubMed Central. Read this recent OnlineOpen article. Yours can be too. Learn more about OnlineOpen.

Read these recently published OnlineOpen Papers:

Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data, C. Kunz et al

A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials, J. Bowden and A. Mander

 Pharmaceutical Statistics OnlineOpen


PSI's Pharmaceutical Statistics Journal Club

The most recent Journal Club, sponsored by Wiley, covered two hot topics; the use of historical control data and data transparency. The event took place on 17 July 2014 with two speakers presenting their papers, Kert Viele (Berry Consultants) and Sara Hughes (GlaxoSmithKline)

Chair: Christine Fletcher, Amgen
Discussant: Andy Grieve, Aptiv Solutions

Speaker: Kert Viele, Berry Consultants
Use of historical control data for assessing treatment effects in clinical trials
Pharmaceutical Statistics, Volume 13, Issue 1, January/February 2014

Speaker: Sara Hughes, GlaxoSmithKline
Preparing individual patient data from clinical trials for sharing: the GlaxoSmithKline approach
Pharmaceutical Statistics, Volume 13, Issue 3, May/June 2014

Full details are available at http://www.psiweb.org/journalclub.

Archive of previous Journal Club meetings

Pharmaceutical Statistics

New Editor-in-Chief

We are delighted to welcome Gerd Rosenkranz as one of three Editors-in-Chief of Pharmaceutical Statistics. After completing an MSc in mathematics and physics, Gerd joined the departments of Biostatistics and Mathematical Modeling at the German Cancer Research Center and received a PhD in mathematics.

He has more that 25 years experience within the pharmaceutical industry, from pre-clinical research work at Hoechst (now Sanofi-Aventis) to clinical development (vaccines, oncology, and recently neuroscience) at Sandoz/Novartis in Basel. He has also published in the areas of safety analysis and missing data, among other topics.

Don't Miss the Latest Pharmaceutical Statistics Special Issue

Pharmaceutical Statistics Special Issue

Special Issue: Focusing on the PSI Special Interest Groups

SEARCH

SEARCH BY CITATION